Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlled beta-receptor blockade with esmolol and flestolol.

V S Murthy1, W H Frishman

  • 1Department of Medicine, University of Wisconsin Medical School, Sinai Samaritan Medical Center, Milwaukee 53201-0342.

Pharmacotherapy
|January 1, 1988
PubMed
Summary

Esmolol, a novel cardioselective beta-blocker, offers rapid titration and quick reversal for critically ill patients. Its ultrashort action allows precise control in managing cardiovascular conditions like supraventricular tachycardia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AIDS and the heart: Clinicopathologic assessment.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same author

Emerging pattern of clozapine prescription in India: a cause for concern?

Acta psychiatrica Scandinavica·2014
Same author

ACE inhibitors and the arterial wall. Introduction.

Postgraduate medicine·2009
Same author

Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancy.

Minerva medica·2006
Same author

Antiplatelet therapy: glycoprotein IIb/IIIa receptor antagonists.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Alcohol as a cardioprotective agent.

Heart disease (Hagerstown, Md.)·2002

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Critical Care

Background:

  • Beta-receptor-blocking agents are mainstays in cardiovascular disease management.
  • Critically ill patients present unique challenges for pharmacotherapy.
  • Novel agents with improved pharmacokinetic profiles are needed.

Purpose of the Study:

  • To introduce esmolol, a novel cardioselective beta-receptor-blocking agent.
  • To highlight the pharmacokinetic advantages of esmolol in critically ill patients.
  • To discuss the clinical applications and safety of esmolol.

Main Methods:

  • Pharmacokinetic analysis of esmolol.
  • Clinical evaluation of esmolol's efficacy and safety.
  • Comparison with existing beta-receptor-blocking agents.

Related Experiment Videos

Main Results:

  • Esmolol is cardioselective, devoid of intrinsic sympathomimetic activity, and has no direct cardiac depressant effect.
  • Esmolol is rapidly metabolized by choline-esterase to an inactive metabolite (ASL 8123).
  • Esmolol possesses an ultrashort elimination half-life of nine minutes, enabling precise titration and rapid reversal of effects.

Conclusions:

  • Esmolol's unique pharmacokinetic properties offer significant advantages for managing cardiovascular diseases in critically ill patients.
  • The ability to titrate and rapidly reverse esmolol's effects enhances patient safety.
  • Esmolol's approval for supraventricular tachycardia and ongoing evaluation of similar agents like flestolol suggest an expanding role for ultrashort-acting beta-blockers.